Biotech has been under fire lately. Few stocks have felt the sting more than BioMarin. Should you be buying the orphan drug maker after its decline? » Subscribe …
source CNBC
BioMarin Pharmaceutical CEO: Orphan Opportunity? | Mad Money | CNBC
Biotech has been under fire lately. Few stocks have felt the sting more than BioMarin. Should you be buying the orphan drug maker after its decline? » Subscribe …
source CNBC
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More